Search bioRxiv⌕ Search

Biology subjects

Kumegawa, K.

Publications and source records attributed to Kumegawa, K..

4 recordsLinked to original sources

Plasticity of extrachromosomal DNA segregation during drug adaptation

Uneven segregation during mitosis is a striking feature of extrachromosomal DNA (ecDNA). Because ecDNA lacks a centromere, it is thought to segregate stochastically and randomly during cell division, thereby generating extensive intratumoral heterogeneity in genomic copy number. Several studies have reported that ecDNA copy numbers can readily change in response to drug treatment, which enables the cells to acquire drug resistance. However, the mechanisms underlying these dynamic changes remain poorly understood --particularly whether such copy-number changes result from static selection of pre-existing clones or from active reconfiguration under drug-induced stress. This key question remains unresolved, mainly due to the absence of technologies capable of tracking ecDNA copy number simultaneously across clones. To overcome this limitation, we developed a high-throughput framework that combines single-cell DNA sequencing with cellular barcoding for clonal tracking of ecDNA copy-number dynamics. The results of single-cell cloning experiments revealed that not all clones exhibit identical segregation modes even under drug-free conditions. Clonal tracking under drug treatment showed that resistant populations do not simply emerge from pre-existing clones with favorable ecDNA states; instead, some clones seemed capable of actively reconfiguring their segregation behavior, possibly involving neuron-like alternation in microtubule organization and intracellular transport pathways, to generate drug-resistant cells. These findings suggest that, although ecDNA might segregate stochastically, it may undergo nonrandom, actively regulated segregation under drug stress. This discovery allows the therapeutically targeting of ecDNA segregation mechanisms to counteract adaptive drug resistance.

cell biology↗

Breast cancer identity is defined by specialized enhancer sets via lysine deacetylation

Breast cancer subtypes are defined by distinct transcriptional programs, yet the epigenetic mechanisms underlying subtype-specific gene regulation remain unclear. Enhancers, key regulators of gene expression and cell identity, are well positioned to define breast cancer subtypes. Here, we identify a previously unrecognized class of enhancers, termed hypoacetylation-defined (HD) enhancers, that regulate cancer-related genes in a luminal breast cancer cell line. HD enhancers are defined by RNA polymerase II dissociation upon lysine deacetylase inhibition, and bidirectional eRNA transcription. They are distinct from super-enhancers, require a specific Mediator subunit for gene-specific transcription, and form extensive chromatin interactions suggestive of a hub-like architecture. Analyses of clinical datasets further identified a subset of HD enhancers, termed HD cluster 1 enhancers, which classify patients into breast cancer subtypes and are associated with expression quantitative trait loci linked to subtype-specific gene expression. This study identifies the lysine deacetylation-regulated cell identity enhancers, which are potential therapeutic targets.

cancer biology↗

Clonal lineage tracing and parallel multiomics profiling reveal transcriptional diversification induced by ARID1A deficiency

Phenotypic heterogeneity among genetically identical cancer cells underpins tumor progression and therapy resistance. However, the mechanism of epigenetic dysregulation that drives such divergence remains unclear. This study introduces integrated multimodal experimental platform specialized in analyzing inter/intraclonal heterogeneity (IMPACH), a scalable platform that integrates lineage tracing, genetic perturbation, and multimodal single-cell analysis. Utilizing IMPACH, results revealed that loss of epigenetic regulators--particularly ARID1A--enhances transcriptomic and epigenetic heterogeneity under controlled conditions. ARID1A deficiency promotes stochastic chromatin opening and induces an atypical gene expression program associated with poor clinical outcomes. Despite increased epigenetic randomness, chromatin changes remain localized to regulatory elements, partially linked to SMARCA4 binding sites. These findings revealed that chromatin remodeling defects promote clonal diversification through both stochastic and constrained mechanisms. Thus, owing to its scalability and versatility, IMPACH provides a robust framework for elucidating how epigenetic perturbations shape cellular heterogeneity in cancer.

cancer biology↗

Human TIMELESS, a potential circadian clock regulator, plays an essential role in survival and reawakening of metastasis-initiating cells in bone

Bone metastasis is becoming increasingly common globally. In such cases, cancer cells disseminate from the primary site to bone, subsequently entering a dormant state. Following a certain incubation period, the cells reawaken and grow, forming a metastatic mass. These dormant cells are called metastasis-initiating cells (MICs), but their survival and reawakening are poorly understood. Here, we established an in vivo MIC-reawakening mouse model in bone. Microarray analysis demonstrated enrichment for mitochondrial oxidative phosphorylation (OXPHOS) and fatty acid synthesis in isolated MICs. In addition, transcriptional regulator TIMELESS was identified as an independent poor prognostic factor by using clinical transcriptomic datasets, which was validated by immunostaining on 209 breast cancer cases. TIMELESS-deficient breast, prostate, and bladder cancer cell lines exhibited reduced viability and MIC reawakening in bone. Single-cell analysis on the epigenetic landscape of MICs revealed that motif activities of CLOCK and BMAL1/ARNTL were enhanced in a cluster with increased TIMELESS accessibility scores. As TIMELESS regulates stemness through the OXPHOS metabolic state, an inhibitor targeting the metabolic pathway, MP-A08, was identified to suppress MIC reawakening and growth in bone more efficiently than cisplatin. These results suggest that TIMELESS regulates survival and reawakening in MICs and MP-A08 could contribute to adjuvant therapeutic strategies.

cancer biology↗